Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
PRLD
PRLD
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PRLD News
Precision Biologics Market Awakens to $71 Billion Opportunity
Feb 05 2026
Globenewswire
Precision Biologics Market Awakens to $71 Billion Opportunity
Feb 05 2026
Newsfilter
Prelude Therapeutics Receives FDA Clearance for PRT12396 Trials
Feb 03 2026
stocktwits
Prelude Therapeutics Receives FDA Clearance for Blood Cancer Trial
Feb 03 2026
seekingalpha
Prelude Therapeutics Receives FDA Clearance for Phase 1 Study of PRT12396
Feb 03 2026
Newsfilter
Oncolytics Biotech Secures FDA Approval with 33% Efficacy for New Drug
Dec 16 2025
Newsfilter
Oncolytics Biotech Secures FDA Approval with 33% Efficacy for Pelareorep in Colorectal Cancer
Dec 16 2025
Globenewswire
Prelude Therapeutics Unveils JAK2 Inhibitor, Plans IND Filing in Q1 2026
Dec 06 2025
Globenewswire
Prelude Therapeutics Unveils JAK2 Inhibitor with IND Filing Expected in Q1 2026
Dec 06 2025
Newsfilter
PRLD Investors Can Participate in Prelude Therapeutics Incorporated Fraud Investigation Led by Schall Law Firm
Nov 19 2025
Globenewswire
Targeted Cancer Treatments Accelerate as Precision Medicine Market Exceeds $106 Billion
Nov 19 2025
Globenewswire
Prelude Therapeutics Inc Reports Smaller Q3 Loss, Surpassing Expectations
Nov 12 2025
NASDAQ.COM
Dow Falls More Than 400 Points; Pfizer Reports Earnings Exceeding Expectations
Nov 04 2025
Benzinga
Prelude Therapeutics Unveils Key Business Developments
Nov 04 2025
Newsfilter
Most Active Stocks in Pre-Market Trading on November 4, 2025: TSLL, SQQQ, PRLD, INTC, IHRT, PLTR, PFE, KORE, C, UBER, APH, NIO
Nov 04 2025
NASDAQ.COM
Incyte signs option deal with Prelude for JH2 inhibitor initiative
Nov 04 2025
SeekingAlpha
Show More News
